Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?
暂无分享,去创建一个
G. Tocci | P. Spallarossa | P. Ameri | A. Battistoni | G. Tini | M. Sarocchi | E. Arboscello | I. Porto